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Cytokeratin-positive cells in bone marrow for identifying distant
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Summary Direct evidence of tumour seeding in distant organs at the time of surgery for gastric cancer is not
available. An immunocytochemical assay for epithelial cytokeratin protein may fill this gap since it is a feature
of epithelial cells that would not normally be present in bone marrow. The bone marrow of 46 patients with
primary gastric cancer was examined for tumour cells, using immunocytochemical techniques and antibody
reacting with cytokeratin, a component of the intracytoplasmic network of intermediate filaments. The
monoclonal antibody CK2 recognises a single cytokeratin polypeptide (human cytokeratin no. 18) commonly
present in epithelial cells. The expression of tumour-suppressor genes p53 and RB for the primary lesion was
also determined using the monoclonal antibodies PAb 1801 and 3H9 respectively, and the proliferating activity
was determined by the Ki-67 antigen labelling index for MIB-1 antibody staining. Of these 46 patients, 15
(32.6%) presented with cytokeratin-positive cells at the time of primary surgery. The positive findings were
related to the undifferentiated tissue type and to the prominent depth of invasion, but not to other
clinicopathological factors. In 2 of 15 (13.3%) patients, the depth of invasion was limited to the mucosa. The
metastatic potential to bone marrow did not relate to expressions of p53 and RB genes, or to the proliferating
activity of MIB-1 staining for the primary lesion of gastric cancer. As tumour cells in bone marrow are
indicative of the general disseminative capability of an individual tumour, this technique may be useful for
identifying patients at high risk of metastasis from a gastric tumour.
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A proportion of patients who present with gastric cancer
have disseminated disease that cannot be detected by cur-
rently available methods (Koga et al., 1987; Maehara et al.,
1992). Despite radical excision of the primary tumour, almost
half the number of patients with gastric cancer will die from
progression of a distant tumour. Prognostic criteria, i.e., the
depth of invasion, tissue differentiation, tumour size and the
spread to lymph nodes have been used in an attempt to
identify a group of patients who have local disease but are at
high risk of developing metastases (Maehara et al., 1991;
Moriguchi et al., 1992). In these patients, the principal cause
of death is metastasis occurring early in tumour develop-
ment, and which leads to locoregional or distant tumour
progression in later stages of the disease. Recent studies were
done on DNA content, proliferative activity, abnormalities of
oncogenes or tumour-suppressor genes, the objective being to
determine whether these factors could serve as precise
indicators of the clinical course (Korenaga et al., 1990;
Mizutani et al., 1993; Joypaul et al., 1994). A feature com-
mon to all these prognostic factors is that, from excised
tumour material, one attempts to extrapolate to the malig-
nant potential of occult cells that may possibly be present in
the patient. Diagnostic techniques currently available are not
sufficiently sensitive to detect unicellular or oligocellular mic-
rometastasis.
Monoclonal antibodies used in conjunction with immuno-
cytochemical procedures are potent probes to identify indi-
vidual tumour cells in bone marrow aspirates from patients
with various cancers (Schlimok and Riethmuller, 1990a). As
cytokeratin proteins are essential constituents of the cyto-
skeleton of both normal and malignant epithelial cells, they
can serve as reliable markers for the epithelial origin of cells
(Debus et al., 1984). In particular, the use of a monoclonal
antibody against the cytokeratin component no. 18 expressed
by all tumour cells derived from simple epithelia facilitates
identification of 1 in 105 epithelial tumour cells in bone
marrow of patients with colorectal, gastric, mammary, lung
and prostate cancers (Mansi et al., 1987; Schlimok and
Riethmiiller, 1990a; Lindemann et al., 1992; Pantel et al.,
1993a; Oberneder et al., 1994). Schlimok and Riethmuller
(1990a) reported that the presence of micrometastasis in the
bone marrow was related to lymph node and to distant
metastases and was frequent in diffuse forms of gastric
cancer. Lindemann et al. (1992) reported the post-operative
prognostic significance of micrometastasis in bone marrow
for colorectal cancer patients. Richard et al. (1991) found
that micrometastasis in bone marrow is a predictor of an
early relapse for breast cancer and Pantel et al. (1993b) noted
that breast cancer cells in bone marrow have a greater pro-
liferating potential, as determined by the level of erbB-2
expression.
We examined disseminated tumour cells in bone marrow,
as representative of a part of the tumour that usually remains
after surgery and that provides direct evidence of diss-
eminative potential of the tumour cells. We compared the
presence of cytokeratin-positive cells in the bone marrow
with clinicopathological factors, tumour-suppressor genes
p53 and RB expressions (Kakeji et al., 1993; Yonemura et
al., 1993) and the proliferating activity determined by the
MIB-1 staining of the primary lesion (Cattoretti et al., 1992).
In patients entered into this study, bone marrow aspirates
were taken under general anaesthesia, immediately before the
initial surgery.
Patients and methods
Patients
This study included 46 unselected Japanese patients with
primary gastric cancer, all of whom underwent gastric resec-
tion in the Department of Surgery II, Kyushu University,
Japan from 1992 to 1994. Pathological diagnosis and class-
ification of the resected gastric cancer tissues were made
according to the General Rules for the Gastric Cancer Study
in Surgery and Pathology in Japan (Japanese Research
Society for Gastric Cancer, 1981a,b, 1993). Informed consent
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to participate in this study was obtained from all patients
before operation.
Bone marrow specimens
Preoperatively, 1 ml of bone marrow aspirates from the ster-
num were taken in syringes containing 100 units heparin ml-'
marrow and the bone marrow cells were prepared by the
method of Lindemann et al. (1992). After dilution with 10 ml
Hanks' balanced salt solution, marrow fat was separated by
centrifugation (180g, 10 min). After density centrifugation
through Ficoll-Hypaque (400g, 30 min), mononuclear cells
were collected from the interphase. Washed twice in
phosphate-buffered saline (PBS) and centrifuged (200g,
5 min), the cells were then suspended with 0.5 ml of RPMI-
1640 medium containing 10% of fetal calf serum yielding a
concentration of 2 x 106 ml-Ion glass slides and were fixed
with acetone (30 min, 4°C). Routinely, 10-20 slides contain-
ing 6 x 105 nucleated cells were examined for each patient.
One additional slide served as an IgG isotype control. For
immunostaining, the monoclonal antibody CK2 (IgG,; Boeh-
ringer Mannheim, Germany) was used at a concentration of
0.2tig ml-'. This antibody recognises intracellular cyto-
keratin component no. 18, an intermediate filament represen-
ting the intracellular network of the cytoskeleton that is
expressed in simple epithelia and nowhere else. The antibody
reaction was developed using the labelled avidin-biotin
(LAB) technique (Guesdon et al., 1979), and biotin-labelled
antibody and alkaline phosphatase (AP)-labelled avidin were
used sequentially. Naphthol-AS-BI-phosphate was used as a
substrate of ALP and the released naphthol-AS-BI was
coupled with hexazotised new fuchsin. Endogenous phos-
phatase was inhibited by preincubation with levamisole. Cells
containing cytokeratin no. 18 were stained bright red.
p53 staining
Tissue sections from the 46 patients were immunostained
with a monoclonal antibody against p53 (PAb 1801, Onco-
gene Science, USA) (Lauwers et al., 1993). Xylene was used
to remove paraffin from the sections, then the sections were
progressively hydrated in decreasing concentrations of
alcohol. The slides were placed in a thermoresistant beaker
filled with 0.1 M PBS (pH 7.4) and autoclaved at 121°C to
allow the fixed, embedded tissue antigen to react with the
monoclonal antibody. The sections were then cooled down to
room temperature for about 20 min and rinsed in PBS. These
sections were then covered with normal rabbit serum for
15 min to reduce non-specific staining and incubated with a
1:100 dilution of primary antibody at room temperature for
1 h. Next the sections were washed with PBS, incubated with
a 1:600 dilution of biotinylated goat anti-mouse IgG (Dako,
Denmark) at room temperature for 30 min then covered with
a 1:1000 dilution of labelled streptavidin peroxidase (Dako)
at room temperature for 30 min. The antibody was localised
with 3,3'-diaminobenzidine tetrahydrochloride and 0.065%
sodium azide was used to block endogenous peroxidase.
We stained both the deep periphery of the tumour and
adjacent tumour-free tissue. A distinct nuclear immunoreac-
tion for p53 was judged positive. In the positive cells the
nuclear staining pattern was diffuse with little variation.
When 10% of the cancer cells showed a positive nuclear
staining, a positive staining was defined (Kakeji et al., 1993).
RB and MIB-I staining
Paraffin was removed in xylene and the sections then exposed
to graded concentrations of alcohol. Trypsin (Difco
Laboratories, USA) (0.1%) treatment was done and the
slides were placed in a thermoresistant beaker filled with
0.1 M PBS (pH 7.4) and were autoclaved at 121°C. Then the
sections were cooled down to room temperature for about
20min and rinsed in PBS. The tissue sections were then
covered with a monoclonal antibody 3H9 for RB protein
(Medical & Biological Laboratories, Japan) (Yonemura et
al., 1993) or a monoclonal antibody MIB-1 for Ki-67 antigen
(Immunotech, France) (Cattoretti et al., 1992), with a 1:40
dilution or 1:100 dilution of antibody respectively, for 60 min
at room temperature, then with biotinylated rabbit anti-
mouse IgG (1:600 for 30 min), and finally with the labelled
streptavidin peroxidase. Peroxidase labelling was developed
with 3,3'-diaminobenzidine and sodium azide, and the sec-
tions were counterstained with haematoxylin. All stained
nuclei were scored as positive for MIB-1. The RB and MIB-1
labelling indices were determined by observing 1000 nuclei in
areas of the section with the highest labelling frequency and
the percentage of labelled nuclei was used for analysis.
Statistical analysis
The BMDP Statistical Package program (BMDP; Los
Angeles, CA, USA) for the IBM (Armonk, NY, USA) 4381
mainframe computer was used for all analyses (Dixon, 1988).
The BMDP P4F and P3S programs were used for the chi-
square test and the Mann-Whitney test to compare data on
patients with and without cytokeratin-positive cells in bone
marrow. The level of significance was P<0.05.
Results
Clinicopathologicalfactors
Bone marrow aspirates of 46 patients with gastric cancer
were examined using the monoclonal antibody CK2 directed
against the cytokeratin polypeptide no. 18 that is exclusively
expressed in all simple epithelia and in 100% of transformed
cells derived thereof. Fifteen of 46 (32.6%) aspirates from
patients comprising all tumour advances were positive for
epithelial cells (Figure 1). The alkaline phosphatase-stained
Figure 1 Microphotograph of micrometastases in the bone mar-
row. High-power photomicrograph of bone marrow specimens
for those with one cytokeratin-positive cell (a) or a small cluster
of cells (b) (original magnification x 1000).cells in cytocentrifuge preparations appeared as red single or
clustered cells, and were present at a frequency of 104-10
nucleated cells. These cells were de-stained and confirmed as
cancer cells by Papanicolaou staining. The positive findings
did not depend on sex, age or location of the tumour. In
cases of cytokeratin-positive cells, undifferentiated tissue type
was more frequent and the depth of invasion was more
prominent. Lymphatic and vascular involvement and metas-
tasis to lymph nodes, peritoneal dissemination and liver
metastasis showed no relation with the presence of micro-
metastasis in the bone marrow (Table I).
Relation between the presence ofmicrometastasis andp53
staining
We determined the relation between the detection of
cytokeratin-positive cells in the bone marrow and abnormal
p53 staining in the primary lesion. The positive rate of p53
was 25.8% (8/31) for cytokeratin-negative patients and
26.6% (4/15) for cytokeratin-positive ones, with no
significant difference (Table II).
Relation between the presence ofmicrometastasis and the RB
staining
The labelling index of RB staining of primary lesion was
determined between the cytokeratin-negative and -positive
groups. RB labelling index was 56.5 ± 25.6% for the
cytokeratin-negative group and 66.9 ± 20.5% for the cyto-
keratin-positive group, with no significant difference (Table
III).
Relation between the presence ofmicrometastasis and the
MIB-I staining
The labelling index of MIB-1 staining of primary lesion was
determined between the cytokeratin-negative and -positive
groups. MIB-1 staining was 60.3 ± 20.9% for the cyto-
keratin-negative group and 58.9 ± 20.5% for the cytokeratin-
positive group, with no significant difference (Table III).
Discussion
Even after a curative resection there can be recurrences in
patients with advanced or even early gastric cancer (Ichiyoshi
et al., 1990; Maehara et al., 1992). A highly sensitive method
is needed to predict metastatic potential and clinical outcome
and to design pertinent treatments. Gastric cancer markers
may provide prognostic information independent of and
complementary to conventional parameters, including growth
potential, oncogenes, tumour-suppressor genes and DNA
flow cytometry, as well as other growth factors (Korenaga et
al., 1990; Mitzutani et al., 1993; Joypaul et al., 1994). The
common characteristic of these prognostic factors is that they
correlate a property of the primary tumour with the subse-
quent outcome.
The method we have described here relates to an aspect of
the actual behaviour of the tumour, microscopic dissemina-
tion of cancer cells in the bone marrow. Cytokeratin expres-
sion is conserved in nearly all normal epithelial cells as well
as in primary and metastatic carcinoma cells (Debus et al.,
1984) and is absent in haematopoietic and lymphatic cells. As
cytokeratin-positive cells were not detected in bone marrow,
they are suitable to detect micrometastases present in the
marrow (Schlimok and Riethmiiller, 1990a). There are
reports of micrometastasis in the bone marrow of patients
with colorectal or breast cancer (Mansi et al., 1987; Schlimok
and Riethmiiller, 1990a; Lindemann et al., 1992; Pantel et al.,
1993a). The evidence of micrometastasis meant an early
relapse and the clinical outcome for these patients could be
predicted (Schlimok et al., 1990b; Cote et al., 1991;
Lindemann et al., 1992;). We also found cytokeratin-positive
cells in lymph nodes in 22% of our patients with node-
Gastric cancer and bone marrowmicrometastasis
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Table I Clinicopathological characteristics of patients with gastric
cancer with and without cytokeratin-positive cells in the bone
marrow
Cytokeratin- Cytokeratin-
negative cases positive cases
Variable (n=31) (n= 15) P-value
Sex
Male 19 10 NS
Female 12 5
Age (years) 61.0± 13.1a 58.3 12.7a NS
Tumour maximal
diameter (cm) 5.60 ± 3.84a 7.50 ± 3.82 NS
Histology
Differentiated 18 3 P<0.05
Undifferentiated 13 12
Depth of penetration
Mucosa 7 2 P<0.05
Submucosa 7 0
Muscularis propria 4 1
Subserosa 6 6
Serosa 6 5
Invasion into adjacent 1 1
organs
Lymph node metastasis
Negative 15 8 NS
Positive 16 7
Peritoneal dissemination
Negative 30 12 NS
Positive 1 3
Liver metastasis
Negative 31 14 NS
Positive 0 1
amean±standard deviation; NS, not significant.
Table 11 Rate of p53 overexpression in gastric cancer with or
without cytokeratin-positive cells in the bone marrow
Without With
cytokeratin- cytokeratin-
positive cells positive cells
Factor (n=31) (n= 15) P-value
p53 expression
Negative 23 11 NS
Positive 8 4
NS, not significant.
Table III Biological character evaluated by RB and MIB-1 labelling
in gastric cancer with or without cytokeratin-positive cells in the
bone marrow
Without With
cytokeratin- cytokeratin-
positive cells positive cells
Factor (n=31) (n= 15) P-value
RB labelling (%) 56.5 ± 25.6a 66.9 ± 31.4 NS
MIB-1 labelling (%) 60.3 ± 20.9a 58.9 ± 20.5 NS
aMean± standard deviation. NS, not significant.
negative early gastric cancer and who died with a recurrence
(Maehara et al., 1995).
In the present report, clinicopathological features and the
malignant potential of primary tumour were examined for
patients with epithelial cells in their marrow at the time of
surgery for the primary tumour. The presence of micrometas-
tatic cells at this time correlated with tissue differentiation
and the depth of invasion. Micrometastasis was noted in two
patients with mucosal gastric cancer, thus seeding of cancer
cells can occur even in the early stage of the cancer. Schlimok
& Riethmiiller (1990a) found the cytokeratin-positive rate to
be 12.5% for node-negative gastric cancer, but in our
patients the rate was 8/23 (34.8%). We examined the
biological nature of cancer cells in the primary lesion by
determining the expression of p53 and RB proteins andGastric cancer and bone marrow micrometastasis
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MIB-1 staining. The p53 and RB abnormalities are reported
to be related to aggressive behaviour of cancer cells for
serosal invasion, lymph node metastasis, peritoneal
dissemination and liver metastasis of gastric cancer, and the
prognosis was poor (Yonemura et al., 1993; Joypaul et al.,
1994). MIB-1 reacts with a nuclear non-histone protein (Ki-
67 antigen) in all active parts of the cell cycle and the level of
labelling index relates to lymphatic and vascular progression
(Cattoretti et al., 1992). As similar distributions of markers
of tumour malignancy and proliferation were found on the
primary lesion, irrespective of the presence of cytokeratin-
positive cells in bone marrow, characteristics of the metast-
asis to bone marrow and the outgrowth of tumour cells into
visible metastases need to be clarified.
Overt bone or skeleton metastases are rare in patients with
gastric cancer, however, bone marrow is distinctly more often
involved than expected from the clinical findings (Koga et al.,
1987; Lindemann et al., 1992). The apparent discrepancy
between clinically rare bone metastases and the marrow
micrometastases frequently detected by immunocytochem-
istry may be explained by a reduced proliferative behaviour
of the cells and often invoked state ofdormancy (Schlimok et
al., 1990b; Cote et al., 1991). The capacity of the tumour cells
to proliferate in the bone marrow and to manifest metastasis
depends on the microenvironment. The presence of
disseminated cells in bone marrow could also indicate that
cancer cells have reached the peritoneum, liver or lung
(Lindemann et al., 1992). Therefore, these patients may have
complications arising from peritoneal dissemination or liver
metastasis with no manifest metastasis in the bone marrow
(Maehara et al., 1991; Moriguchi et al., 1992).
Cytokeratin-positive cells in the bone marrow of gastric
cancer patients may serve as valid indicators of the intrinsic
metastatic activity of an individual tumour. Patients presen-
ting with disseminated cytokeratin-positive cells at the time
of primary surgery have to be closely followed and the
possible presence of distant metastasis should always be a
concern for attending physicians.
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